Washington DC based Attorney Michael Gallant focuses his practice on product liability and mass torts. More specifically Michael heads the medical device and pharmaceutical drug litigation division of Bernheim Dolinsky Kelley.
Michael received his law degree from Catholic University of America in 1995. He is a member of the New York Bar since 1995 and the District of Columbia Bar since 1996. Prior to practicing with the firm, Michael managed the pharmaceutical and medical device practice at Pollack & Flanders, LLP. Prior thereto he was a partner of Ashcraft & Gerel, LLP, and Herman, Mathis, Casey, Kitchens & Gerel, LLP.
Michael has dedicated his career to helping clients injured by defective products. He has handled thousands of cases for clients concerning medical device litigation and pharmaceutical drug litigation. Attorney Gallant has been instrumental in pursuing large multinational corporations in numerous litigations. Some of his past experience includes extensive litigation concerning the diet drugs Fen-Phen and Redux®, silicone gel breast implants, the gastroesophageal reflux medication Propulsid, the hormone replacement therapy Prempro™, the Ortho Evra Birth Control Patch, Guidant Internal Cardiac Defibrillators.
“Combating the excesses of the medical device and pharmaceutical industry is important work. I am proud to have spent my entire career securing compensation for patients who have been misled and injured by manufacturers of pharmaceutical products and medical devices.”
– Michael E. Gallant
Today, Attorney Gallant is investigating and prosecuting claims for injuries arising out of the use of the diabetes drug Avandia, Depuy Orthopedic’s ASR Hip Replacement Systems, Zimmer Nexgen Knee Replacement Systems, Medtronic Infuse bone morphogenic protein (BMP), Stryker Rejuvenate and ABG II hip replacement systems, the anti-coagulant drug Pradaxa, transvaginal mesh systems, Fresenius dialysis and the diabetes drug Actos.
Helping families across the United States to get the justice and compensation they are due.